BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
See today's BioWorld
Home
» Big bounce for Jounce: Firm lands $2.56B Celgene immuno-oncology collaboration
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Big bounce for Jounce: Firm lands $2.56B Celgene immuno-oncology collaboration
July 20, 2016
By
Michael Fitzhugh
No Comments
Jounce Therapeutics Inc. will receive a $225 million up-front payment and a $36 million equity investment as part of a five-candidate immuno-oncology (I-O) collaboration with Celgene Corp.
BioWorld